1-6 of 6
Bruce R. Blazar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Shernan G. Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A. Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh, Estefania Julia, Joseph Maakaron, Veronika Bachanova, Najla El Jurdi, Margaret L. MacMillan, Daniel J. Weisdorf, Martin Felices, Jeffrey S. Miller, Bruce R. Blazar, Marco L. Davila, Brian C. Betts
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1114–1124.
https://doi.org/10.1158/1078-0432.CCR-22-2837
Published: 14 March 2023
View article titled, Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Open the PDF for Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality in another window
Includes: Supplementary data
Journal Articles

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Joseph Pidala, Kelly Walton, Hany Elmariah, Jongphil Kim, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan G. Faramand, Marco L. Davila, Michael L. Nieder, Elizabeth M. Sagatys, Shernan G. Holtan, Nicholas J. Lawrence, Harshani R. Lawrence, Bruce R. Blazar, Claudio Anasetti, Said M. Sebti, Brian C. Betts
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2712–2722.
https://doi.org/10.1158/1078-0432.CCR-20-4725
Published: 15 May 2021
View article titled, Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Open the PDF for Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results in another window
Includes: Supplementary data
Journal Articles

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Daniel A. Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J. Lenvik, Angela Panoskaltsis-Mortari, Michael R. Verneris, Jakub Tolar, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (14): 3440–3450.
https://doi.org/10.1158/1078-0432.CCR-15-2710
Published: 14 July 2016
View article titled, IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function
Open the PDF for IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function in another window
Includes: Supplementary data
Journal Articles

Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen

Michael R. Olin, Brian M. Andersen, David M. Zellmer, Patrick T. Grogan, Flavia E. Popescu, Zhengming Xiong, Colleen L. Forster, Charlie Seiler, Karen S. SantaCruz, Wei Chen, Bruce R. Blazar, John R. Ohlfest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4800–4808.
https://doi.org/10.1158/1078-0432.CCR-10-1572
Published: 29 September 2010
View article titled, Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen
Open the PDF for Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen in another window
Journal Articles

CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma

Brenda J. Weigel, David A. Rodeberg, Arthur M. Krieg, Bruce R. Blazar
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (8): 3105–3114.
Published: 11 August 2003
View article titled, CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma
Open the PDF for CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma in another window
Journal Articles

A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities

Francisco Bracho, Mark D. Krailo, Violet Shen, Sharon Bergeron, Virginia Davenport, Wen Liu-Mares, Bruce R. Blazar, Angela Panoskaltsis-Mortari, Carmella van de Ven, Rita Secola, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, Mitchell S. Cairo
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 58–67.
Published: 01 January 2001
View article titled, A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
Open the PDF for A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities in another window